Chardan Capital Cuts Femasys (NASDAQ:FEMY) Price Target to $10.00

Femasys (NASDAQ:FEMY – Free Report) had its price objective decreased by Chardan Capital from $12.00 to $10.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Chardan Capital currently has a buy rating on the stock. Separately, HC Wainwright lowered their price objective on Femasys from $13.00 to $12.00 and set a […]

Leave a Reply

Your email address will not be published.

Previous post Robert W. Baird Trims Mersana Therapeutics (NASDAQ:MRSN) Target Price to $3.00
Next post Caribou Biosciences’ (CRBU) “Buy” Rating Reaffirmed at HC Wainwright